英国公司Hemogenyx获得60万英, 开始对新的AML治疗进行临床试验. UK firm Hemogenyx secures £600,000 to begin clinical trials for new AML treatment.

英国生物制药公司Hemogenyx Pharmaceuticals获得了60万英,开始对一种针对急性髓性白血病 (AML) 的新型化学抗原受体T细胞治疗进行I期临床试验. Hemogenyx Pharmaceuticals, a UK biopharmaceutical firm, secured £600,000 to begin Phase I clinical trials for a new Chimeric Antigen Receptor T-cell therapy targeting acute myeloid leukemia (AML). 这项投资将为试验的开始提供资金,并可能为AML患者提供新的治疗选择. The investment will fund the trial's start and potentially offer new treatment options for AML patients. 预计该公司的新股票将在2024年11月15日之前在伦敦证券交易所进行交易。 The company's new shares are expected to be traded on the London Stock Exchange by November 15, 2024.